New Year's Eve Perils: Tips for Beating Insomnia and Staying Healthy

Strategic Insights -

New Year's Eve festivities often come with a price: disrupted sleep patterns and health concerns. As millions of people gather to celebrate the start of a new year, many will find themselves sacrificing sleep for fun and festivities. However, poor sleep can have serious consequences for overall health, including increased risk of chronic diseases, mental health issues, and reduced productivity. To combat the perils of inadequate sleep, here are some expert tips and notable news from the pharmaceutical and financial industries.

Key Takeaways:

  • Over 50 million people worldwide suffer from overactive bladder, a condition that can be embarrassing to discuss, but now has a new once-a-day treatment option with the FDA-approved Detrol(TM) LA capsules (tolterodine tartrate).
  • Type 2 diabetes, a disease with serious consequences, affects an estimated 17 million Americans, and a new treatment option has been approved by the FDA for Starlix(R) (nateglinide).
  • A financial plan is crucial for investors, serving as a roadmap for navigating the complexities of financial markets, just like a roadmap guides travelers.
  • Insomnia and inadequate sleep patterns can lead to chronic diseases, mental health issues, and reduced productivity.
  • The new year's festivities may be fun, but they also come with health concerns; prioritizing sleep and overall well-being is essential for maintaining good health.

Statistics:

  • 50 million people worldwide suffer from overactive bladder.
  • 17 million Americans have type 2 diabetes.
  • Detrol(TM) LA (tolterodine tartrate) capsules are a new once-a-day drug therapy approved by the FDA for overactive bladder relief.
  • Starlix(R) (nateglinide) is a new treatment option approved by the FDA for type 2 diabetes.
  • The perils of inadequate sleep can have serious implications for overall health.

Sources:

  • (Source: Detrol(TM) LA, FDA-approved for overactive bladder)
  • (Source: Starlix(R), FDA-approved for type 2 diabetes)
  • (Source: Merrill Lynch, providing financial plans for investors)